MyFinsight
Home
Blog
About
Contact
Download
Download image
Gain on fair value
adjustments
$5,379,500
(567.91%↑ Y/Y)
Research and development
incentive award
-$478,959
(-56.40%↓ Y/Y)
Interest income, net
$167,311
(446.50%↑ Y/Y)
Total other income
$5,890,111
(232.44%↑ Y/Y)
(loss) gain on foreign
currency transactions
-$135,659
(-121.55%↓ Y/Y)
Income (loss) before
income taxes
$1,829,298
(194.70%↑ Y/Y)
Income tax benefit
(expense)
-$34,794
(-399.72%↓ Y/Y)
Unrealized gain (loss) on
foreign currency...
$570,580
(144.28%↑ Y/Y)
Loss from operations
-$4,060,813
(-9.65%↓ Y/Y)
Net income (loss)
$1,864,092
(195.92%↑ Y/Y)
Total other
comprehensive income (loss)
$570,580
(144.28%↑ Y/Y)
Total operating
expenses
$4,060,813
(-6.99%↓ Y/Y)
Total comprehensive
income (loss)
$2,434,672
(175.34%↑ Y/Y)
General and
administrative
$2,126,918
(-19.10%↓ Y/Y)
Restructuring costs
$1,236,172
Research and development
$697,723
(-59.83%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)